Latest News
-
Wednesday - July 1, 2020
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer issues new senior bonds with a volume of 6 billion euros
Issuance of four tranches with maturities between 4 and 12 years was substantially oversubscribed » more
-
Wednesday - June 24, 2020
Bayer announces agreements to resolve major legacy Monsanto litigation
Company will make a total payment of $10.1 billion to $10.9 billion (EUR 9.1 billion to EUR 9.8 billion) to resolve current and address potential future Roundup™ litigation / Company also resolves dicamba drift litigation for payment of up to $400 million and most PCB water litigation exposure for payment of approximately $820 million / Funding sourced from free cash flow and Animal Health divestment / Bayer is well positioned to deliver science-based solutions to meet global health, nutrition needs » more
-
Wednesday - June 24, 2020
Investor Conference Call
SPEECHES
Bayer announces agreements to resolve major legacy Monsanto litigation » more
-
Friday - June 19, 2020
Not intended for U.S. and UK Media
Bayer contributes an additional 50 million units of treatment to the World Federation of Hemophilia Humanitarian Aid Program
34 low-income countries are already benefiting from Bayer’s recombinant Factor VIII (FVIII) treatments since the start of the partnership with the World Federation of Hemophilia (WFH) in May 2019 / Bayer emphasizes that it will maintain its delivery of life-changing medicines to low-income countries / Bayer also renews its commitment to training and education as well as advocacy for patient access in low-income countries » more
-
Friday - June 19, 2020
Women empowerment in times of COVID-19
Bayer supports “The Challenge Initiative” of Johns Hopkins Bloomberg School of Public Health with 10 million USD
“The Challenge Initiative” to scale up reproductive health for women and girls in urban poverty areas / Participating cities in East Africa, Francophone West Africa, Nigeria, and India / Integrate COVID-19 prevention and education » more
-
Wednesday - June 17, 2020
Bayer to Provide Crop Relief to Two Million Smallholder Farmers Impacted by COVID-19
Through its new “Better Farms, Better Lives” initiative, Bayer will complement its current commitment to support smallholder farmers in key countries by donating seeds and crop protection inputs / The donations help boost food security by supporting up to two million smallholder farmers facing increased challenges as a result of the on-going COVID-19 pandemic » more
-
Wednesday - June 17, 2020
Not intended for U.S. and UK Media
Bayer to highlight latest research on its advancing Oncology portfolio at the AACR20 Virtual Annual Meeting II
Focus on Targeted Thorium Conjugate (TTC) platform, the company’s proprietary targeted alpha therapies program / Synergistic effects of investigational PSMA-TTC in combination with androgen receptor inhibitor darolutamide in preclinical prostate cancer » more
-
Monday - June 15, 2020
Not intended for U.S. and UK Media
Bayer extends clinical development program for finerenone with Phase III study in patients with heart failure and preserved ejection fraction
FINEARTS-HF is the first large-scale, long-term study to investigate the non-steroidal, selective mineralocorticoid receptor antagonist finerenone on morbidity and mortality outcomes in a heart failure patient population » more
-
Friday - June 5, 2020
Not intended for U.S. and UK Media
Bayer submits vericiguat for marketing authorization in the EU and Japan for the treatment of chronic heart failure
Regulatory submissions based on positive data from Phase III VICTORIA study recently published in the New England Journal of Medicine (1) » more
-
Wednesday - June 3, 2020
Bayer Animal Health brings more technologies to warm-water aquaculture
Three agreements enhance its integrated pond water treatment solutions for shrimp » more
-
Friday - May 29, 2020
Not intended for U.S. and UK Media - American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program):
Efficacy of Vitrakvi™ (larotrectinib) further established with continued high response rates and durable response in updated analyses in adult patients and quality of life data in adult and pediatric patients with TRK fusion cancer
71% overall response rate (ORR) per investigator assessment and median duration of response of 35.2 months shown in expanded data set of 116 adult patients with TRK fusion cancer / Among patients with brain metastases, ORR was also 71% / Majority of adverse events (AEs) were grade 1 or 2, no new unexpected grade 3 or 4 AEs were reported / New analysis demonstrates clinically meaningful and sustained improvements in quality of life (QoL) in adult and pediatric patients » more
-
Friday - May 29, 2020
Bayer furthers commitment to greater transparency on glyphosate and stakeholder engagement through new dialogue event series
Stakeholders invited to follow virtual EURACTIV conference on June 4 / Company continues to raise the bar on its own transparency standards / Glyphosate Renewal Group (GRG) relaunches its www.glyphosate.eu website » more
-
Tuesday - May 26, 2020
Bayer to support Harvard Research Study to Evaluate Trust in Science, Including in COVID-19 pandemic » more
-
Friday - May 22, 2020
Not intended for U.S. and UK Media
Bayer submits larotrectinib for marketing authorization in Japan for the treatment of TRK fusion cancer » more
-
Tuesday - May 19, 2020
Nine internationally recognized experts join Sustainability Council
Independent external council to advise Bayer’s Board of Management on consistent implementation of its sustainability targets » more
-
Thursday - May 14, 2020
Not intended for U.S. and UK Media
Bayer and ArcherDX to develop next-generation sequencing (NGS)-based companion diagnostic (CDx) for precision oncology treatment Vitrakvi™
Collaboration focus on development of a companion diagnostic (CDx) for Vitrakvi™ (larotrectinib), the first and only TRK inhibitor approved in Europe for adult and pediatric patients with TRK fusion cancer across all solid tumors / Goal is to advance broad patient access to comprehensive genomic testing through kit-based CDx that can be deployed locally at the site of care in line with Bayer’s commitment to precision medicine » more
-
Wednesday - May 13, 2020
Not intended for U.S. and UK Media - New ARAMIS Phase III data to be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Nubeqa™ (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer
Darolutamide significantly reduced risk of death by 31 percent (HR=0.69, 95% CI 0.53-0.88; p=0.003) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Darolutamide significantly delayed the time to pain progression, time to first initiation of cytotoxic chemotherapy, and time to first symptomatic skeletal event (SSE) / Darolutamide continues to demonstrate a favorable safety profile, with no new safety signals observed, even with a longer treatment duration, allowing men with nmCRPC to maintain their active lifestyle / ARAMIS data will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program on Friday, May 29, and will be available on the ASCO website » more
-
Monday - May 11, 2020
Not intended for U.S. and UK Media
Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program
Data on final analysis of overall survival (OS) from the Phase III ARAMIS trial investigating darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Updated efficacy and safety data for larotrectinib (Vitrakvi™) from an expanded set of adult patients with TRK fusion cancer and a quality of life (QoL) analysis in adult and pediatric patients / New safety and efficacy data from established compounds including radium-223 dichloride (Xofigo™) and regorafenib (Stivarga™) » more
-
Tuesday - April 28, 2020
Online
Annual Stockholders’ Meeting 2020 » more
-
Tuesday - April 28, 2020
CEO Werner Baumann at the Bayer AG Annual Stockholders’ Meeting:
“We’re active in the right businesses”
Coronavirus crisis: Employee safety at the top of the agenda / First DAX company to hold virtual stockholders’ meeting / Strategic and operational targets attained in 2019 / Dividend of 2.80 euros per share proposed / Good start to fiscal 2020 / Winkeljohann to succeed Wenning as Supervisory Board Chairman » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Saturday, August 29, 2020
European Society of Cardiology (ESC) August 29 - September 2, 2020, Amsterdam, Netherlands
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV